Bristol-Myers Squibb has VOLUNTARILY stopped selling Serzone (nefazodone)

September 2004

Bristol-Myers Squibb has VOLUNTARILY stopped selling Serzone (nefazodone) in the U.S.

It's already off the market in Europe and Canada.

The company is not saying...but liver toxicity seems to be part of the reason. FDA added a black box warning 2 years ago.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

a new antidepressant, Cymbalta
Cholesterol a new combo tablet, Vytorin
Diabetes Liver function tests are now required less often for patients taking Actos (pioglitazone) or Avandia (rosiglitazone)
Cardiology Does Altace (ramipril) improve survival after a heart attack better than other ACE inhibitors
Cardiology increased use of spironolactone for heart failure is causing more hospitalizations and deaths
Infectious Diseases A new quinolone, Factive, is hitting the market
Infectious Diseases The CDC is broadening the list of people who should get flu vaccine this year
Bristol-Myers Squibb has VOLUNTARILY stopped selling Serzone (nefazodone)
significant new drug for alcohol dependence called Campral
Renal & Urology Sanctura, a new drug for overactive bladder
Renal & Urology nifedipine or tamsulosin (Flomax) to help expel SMALL kidney stones
Supplements Altovis, Red Bull, Umph, and other energy supplements
Women's Health increasing levothyroxine doses by one-third as soon as pregnancy is confirmed
Women's Health pros and cons of soy for postmenopausal women
Neurology & Pain how to switch opioids